Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis

Background/AimsAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.MethodsWe performed a systematic review on the...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of ophthalmology Ročník 104; číslo 8; s. 1077 - 1084
Hlavní autoři:	Li, Jeany Q, Welchowski, Thomas, Schmid, Matthias, Mauschitz, Matthias Marten, Holz, Frank G, Finger, Robert P
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England BMJ Publishing Group LTD 01.08.2020
Témata:	Age Age Distribution Aged Aged, 80 and over Bias Blindness - epidemiology Classification Epidemiology Estimates Europe - epidemiology European Union - statistics & numerical data Female Humans Incidence Macular degeneration Macular Degeneration - epidemiology Male Meta-analysis Middle Aged Observational Studies as Topic Population Prevalence Sex Distribution Systematic review Trends Vision, Low - epidemiology Visual Acuity Europe United Kingdom > UK Germany epidemiology retina macula
ISSN:	0007-1161, 1468-2079, 1468-2079
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Background/AimsAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.MethodsWe performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.ResultsTwenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.ConclusionsApproximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come.
AbstractList	Background/AimsAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.MethodsWe performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.ResultsTwenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.ConclusionsApproximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come. Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning. We performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050. Twenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050. Approximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come. Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.BACKGROUND/AIMSAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.We performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.METHODSWe performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.Twenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.RESULTSTwenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.Approximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come.CONCLUSIONSApproximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come.
Author	Holz, Frank G Finger, Robert P Mauschitz, Matthias Marten Schmid, Matthias Welchowski, Thomas Li, Jeany Q
Author_xml	– sequence: 1 givenname: Jeany Q orcidid: 0000-0002-9771-3431 surname: Li fullname: Li, Jeany Q email: Robert.Finger@ukbonn.de organization: Department of Ophthalmology, University of Bonn, Bonn, Germany – sequence: 2 givenname: Thomas surname: Welchowski fullname: Welchowski, Thomas email: Robert.Finger@ukbonn.de organization: Department of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany – sequence: 3 givenname: Matthias surname: Schmid fullname: Schmid, Matthias email: Robert.Finger@ukbonn.de organization: Department of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany – sequence: 4 givenname: Matthias Marten surname: Mauschitz fullname: Mauschitz, Matthias Marten email: Robert.Finger@ukbonn.de organization: Department of Ophthalmology, University of Bonn, Bonn, Germany – sequence: 5 givenname: Frank G surname: Holz fullname: Holz, Frank G email: Robert.Finger@ukbonn.de organization: Department of Ophthalmology, University of Bonn, Bonn, Germany – sequence: 6 givenname: Robert P surname: Finger fullname: Finger, Robert P email: Robert.Finger@ukbonn.de organization: Department of Ophthalmology, University of Bonn, Bonn, Germany
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31712255$$D View this record in MEDLINE/PubMed
BookMark	eNqNkUtrVTEUhYNU7G31L0jAiZNT8zivOBCk1CoUdKDjsE-yT5tLHtfkHOX-e9N7W5COOgo7-dbaYa0zchJTREIoZxecy_7DtE27u-UOfEi-EYyrRvK2FeIF2fC2H-vVoE7IhjE2NJz3_JSclbKto-j58IqcSj5wIbpuQ8KPjH_AYzRIIVrqonH2MKWZwi02GT0saGkAs3rI1OItRsywuBQrTa_WnHb4kQIt-7JgqA-GVk-Hfw-GARdoIILfF1dek5cz-IJvHs5z8uvL1c_Lr83N9-tvl59vmkmOw9JMogM1gZjRyLYbYR7UbK1hqKaphZlxY0YFFhUfLc5m7lnHQCkmLTMt75U8J--Pvrucfq9YFh1cMeg9RExr0aLGxYRoh66i756g27Tm-t9KtVIKMfR9X6m3D9Q6BbR6l12AvNePQVbg0xEwOZWScdbGLYeQlgzOa870fXP6_-b0fXP62Fw1GJ8YPO54hlQepVPYPl_1D_3utOY
CitedBy_id	crossref_primary_10_1016_j_exer_2024_109889 crossref_primary_10_1007_s40123_023_00807_9 crossref_primary_10_1186_s12979_025_00511_1 crossref_primary_10_3390_genes14091707 crossref_primary_10_1177_11206721251339231 crossref_primary_10_5507_bp_2022_047 crossref_primary_10_1007_s00347_020_01177_4 crossref_primary_10_1177_25158414211072623 crossref_primary_10_3390_jcm12010295 crossref_primary_10_3390_biomedicines12092092 crossref_primary_10_1167_iovs_66_2_6 crossref_primary_10_1016_j_arr_2025_102771 crossref_primary_10_4103_joco_joco_323_22 crossref_primary_10_1007_s00417_023_06319_3 crossref_primary_10_1136_bmjhci_2024_101236 crossref_primary_10_1080_15548627_2022_2069437 crossref_primary_10_3390_ijms242115523 crossref_primary_10_1055_a_2367_8346 crossref_primary_10_1007_s40123_024_00960_9 crossref_primary_10_1136_bjophthalmol_2020_315890 crossref_primary_10_1167_iovs_65_11_37 crossref_primary_10_1177_25158414211027708 crossref_primary_10_1039_D4NR01995D crossref_primary_10_3390_jpm15050189 crossref_primary_10_1136_bmjophth_2023_001516 crossref_primary_10_1177_1120672120915685 crossref_primary_10_1186_s40942_024_00566_0 crossref_primary_10_3390_ijms232112982 crossref_primary_10_1111_aos_14786 crossref_primary_10_1089_jop_2022_0002 crossref_primary_10_1097_WNR_0000000000001962 crossref_primary_10_1136_bjophthalmol_2020_316195 crossref_primary_10_1038_s41746_024_01018_7 crossref_primary_10_1177_11206721211023725 crossref_primary_10_3390_biomedicines10010159 crossref_primary_10_1080_10715762_2025_2503832 crossref_primary_10_3390_pharmaceutics13101685 crossref_primary_10_1016_j_arr_2025_102796 crossref_primary_10_1136_bmjophth_2023_001525 crossref_primary_10_3390_medicina60101647 crossref_primary_10_1097_APO_0000000000000496 crossref_primary_10_3390_ijms21228484 crossref_primary_10_1016_j_exer_2025_110342 crossref_primary_10_2147_OPTH_S479816 crossref_primary_10_3390_ijtm1010006 crossref_primary_10_3928_23258160_20250108_01 crossref_primary_10_1167_iovs_65_4_2 crossref_primary_10_7759_cureus_75586 crossref_primary_10_3389_fimmu_2023_1163739 crossref_primary_10_1001_jamaophthalmol_2024_0918 crossref_primary_10_1007_s00347_025_02257_z crossref_primary_10_1136_bmjopen_2022_069443 crossref_primary_10_2147_OPTO_S470577 crossref_primary_10_3390_ijerph19159488 crossref_primary_10_3390_cells14171360 crossref_primary_10_1097_IAE_0000000000003369 crossref_primary_10_3390_biomedicines12122828 crossref_primary_10_1016_j_bbrc_2022_07_003 crossref_primary_10_1111_aos_16710 crossref_primary_10_1007_s00417_021_05140_0 crossref_primary_10_1038_s41419_025_07497_0 crossref_primary_10_1186_s40942_022_00363_7 crossref_primary_10_3390_jpm15060246 crossref_primary_10_1016_j_ophtha_2022_02_026 crossref_primary_10_3389_fnut_2024_1435775 crossref_primary_10_1002_j_2040_4603_2024_tb00295_x crossref_primary_10_1016_j_exer_2022_109164 crossref_primary_10_1016_j_exer_2021_108911 crossref_primary_10_1038_s41467_025_55970_3 crossref_primary_10_3389_fendo_2023_1322326 crossref_primary_10_3390_antiox14050561 crossref_primary_10_1055_a_2105_1064 crossref_primary_10_3390_medicina59061110 crossref_primary_10_3389_fmed_2024_1361631 crossref_primary_10_1016_j_bcp_2023_115534 crossref_primary_10_1038_s41433_025_03956_2 crossref_primary_10_1038_s41572_021_00265_2 crossref_primary_10_33393_dti_2024_3213 crossref_primary_10_1007_s00417_024_06421_0 crossref_primary_10_1038_s41433_025_03599_3 crossref_primary_10_1186_s12889_024_17889_0 crossref_primary_10_1007_s40123_023_00753_6 crossref_primary_10_7759_cureus_16392 crossref_primary_10_3346_jkms_2025_40_e128 crossref_primary_10_3390_biom13050832 crossref_primary_10_1167_iovs_63_12_21 crossref_primary_10_1371_journal_pone_0259879 crossref_primary_10_3390_ph17020157 crossref_primary_10_1515_revneuro_2023_0130 crossref_primary_10_1093_hmg_ddac060 crossref_primary_10_3390_cells14090633 crossref_primary_10_1007_s10792_024_03376_3 crossref_primary_10_3390_pharmacy13030068 crossref_primary_10_3390_diagnostics13010130 crossref_primary_10_1177_11206721241310628 crossref_primary_10_3390_life13030814 crossref_primary_10_1080_07853890_2023_2222545 crossref_primary_10_1016_j_cmet_2021_01_011 crossref_primary_10_1080_09286586_2022_2093918 crossref_primary_10_1038_s41598_023_35230_4 crossref_primary_10_3390_jcm11164766 crossref_primary_10_1186_s12886_024_03326_8 crossref_primary_10_1038_s42003_021_01765_3 crossref_primary_10_1038_s44222_024_00210_4 crossref_primary_10_1097_ICO_0000000000003113 crossref_primary_10_1080_13696998_2025_2536420 crossref_primary_10_3389_fpubh_2023_1138428 crossref_primary_10_3390_cells12162092 crossref_primary_10_3390_healthcare10112312 crossref_primary_10_1001_jamaophthalmol_2024_4401 crossref_primary_10_1080_17469899_2023_2267179 crossref_primary_10_1080_02713683_2024_2408757 crossref_primary_10_3390_jcm14113622 crossref_primary_10_3390_jcm12082870 crossref_primary_10_1016_j_mam_2021_101038 crossref_primary_10_1111_aos_17444 crossref_primary_10_1007_s40123_024_00999_8 crossref_primary_10_1136_bjo_2022_321985 crossref_primary_10_1016_j_omtm_2024_101242 crossref_primary_10_1186_s13063_020_04595_6 crossref_primary_10_1055_a_2378_6138 crossref_primary_10_3389_fpsyg_2023_1096215 crossref_primary_10_1186_s12874_021_01356_0 crossref_primary_10_1177_20406223221140395 crossref_primary_10_2147_OPTH_S376199 crossref_primary_10_1038_s41433_021_01646_3 crossref_primary_10_1038_s41374_022_00795_7 crossref_primary_10_1016_j_oret_2023_05_005 crossref_primary_10_3390_jcm13133959 crossref_primary_10_1111_aos_15137 crossref_primary_10_1167_iovs_63_5_30 crossref_primary_10_2174_0929867329666220511142817 crossref_primary_10_1007_s11357_022_00620_5 crossref_primary_10_3390_ijerph192013714 crossref_primary_10_1007_s44411_025_00140_6 crossref_primary_10_1016_j_oret_2024_07_020 crossref_primary_10_1159_000513591 crossref_primary_10_3390_biomedicines11113079 crossref_primary_10_1055_a_2327_8597 crossref_primary_10_3390_jcm12144862 crossref_primary_10_1016_j_survophthal_2024_10_004 crossref_primary_10_1016_j_matdes_2023_112152 crossref_primary_10_3390_biomedicines12040807 crossref_primary_10_1007_s00417_024_06478_x crossref_primary_10_1016_j_bspc_2024_107365 crossref_primary_10_1136_bmjophth_2021_000912 crossref_primary_10_1016_j_apjo_2025_100143 crossref_primary_10_1038_s41556_022_00842_x crossref_primary_10_12968_opti_2021_6_8622 crossref_primary_10_1016_j_heliyon_2024_e41116 crossref_primary_10_3390_antiox10081170 crossref_primary_10_1096_fj_202402041R crossref_primary_10_3390_ph17111440 crossref_primary_10_1080_08164622_2022_2111201 crossref_primary_10_3390_genes11111318 crossref_primary_10_4103_joco_joco_240_20 crossref_primary_10_3390_ijms242216406 crossref_primary_10_1159_000521517 crossref_primary_10_1186_s13643_021_01864_6 crossref_primary_10_18502_jovr_v19i1_15415 crossref_primary_10_1007_s40123_022_00528_5 crossref_primary_10_1001_jamaophthalmol_2021_4601 crossref_primary_10_1007_s00347_024_01992_z crossref_primary_10_1136_bmj_l6455 crossref_primary_10_1055_a_2134_7622 crossref_primary_10_18332_tid_205665 crossref_primary_10_1136_bmjophth_2024_001956 crossref_primary_10_1093_ageing_afae155 crossref_primary_10_3390_jpm12050847 crossref_primary_10_1111_aos_14802 crossref_primary_10_1111_aos_14929 crossref_primary_10_1016_j_survophthal_2020_07_003 crossref_primary_10_3389_fnins_2022_1029473 crossref_primary_10_1038_s41598_025_07299_6 crossref_primary_10_1055_a_2079_1692 crossref_primary_10_1155_2020_8848336 crossref_primary_10_1371_journal_pone_0293143 crossref_primary_10_1016_j_ajo_2021_10_008 crossref_primary_10_1016_j_bcp_2025_116902 crossref_primary_10_3390_foods12030508 crossref_primary_10_3390_antiox12122072 crossref_primary_10_1111_opo_13392 crossref_primary_10_3390_cells11213453 crossref_primary_10_1111_opo_13393 crossref_primary_10_1523_JNEUROSCI_0283_25_2025 crossref_primary_10_1007_s40123_024_00901_6 crossref_primary_10_1016_j_aquatox_2022_106295 crossref_primary_10_1136_bjophthalmol_2020_316820 crossref_primary_10_3390_cells12141902 crossref_primary_10_1111_aos_70006 crossref_primary_10_1007_s00347_024_02181_8 crossref_primary_10_1111_aos_16646 crossref_primary_10_1007_s00417_020_04893_4 crossref_primary_10_1038_s41379_021_00887_7 crossref_primary_10_1096_fj_202301020RR crossref_primary_10_3390_ijms21218242 crossref_primary_10_1007_s00417_022_05885_2 crossref_primary_10_3341_kjo_2020_0109 crossref_primary_10_3390_medicina60122072 crossref_primary_10_1167_iovs_64_13_34 crossref_primary_10_1016_j_ejps_2025_107156 crossref_primary_10_3390_life12010036 crossref_primary_10_3389_fped_2022_735335 crossref_primary_10_1007_s40123_024_01030_w crossref_primary_10_1016_j_ajo_2023_07_006 crossref_primary_10_1186_s12889_025_23680_6 crossref_primary_10_3390_antiox14060646 crossref_primary_10_3390_vaccines10111878 crossref_primary_10_1002_14651858_CD009300_pub3 crossref_primary_10_1007_s00417_022_05919_9 crossref_primary_10_1038_s41598_024_63327_x crossref_primary_10_3389_fphar_2024_1507860 crossref_primary_10_1186_s43058_024_00667_9
Cites_doi	10.1016/j.ophtha.2004.07.020 10.1038/eye.2017.30 10.1001/jama.295.6.676 10.1016/j.ajo.2005.05.002 10.1007/s12603-010-0131-9 10.1016/j.ajo.2015.04.003 10.1111/aos.12842 10.1080/08820538.2017.1316861 10.1016/j.ophtha.2011.09.027 10.1136/bjophthalmol-2014-305768 10.1093/biomet/37.3-4.256 10.1016/j.ophtha.2004.11.040 10.1016/j.ajo.2014.05.027 10.1016/j.ajo.2006.07.042 10.1001/archopht.124.4.529 10.1016/j.ophtha.2012.03.016 10.1016/j.ophtha.2012.10.036 10.1016/S0039-6257(05)80092-X 10.3109/09286586.2013.867512 10.1001/jamaophthalmol.2018.0504 10.1016/S2214-109X(13)70145-1 10.1371/journal.pone.0167181 10.1016/S0161-6420(95)31034-2 10.3109/09286586.2011.574334 10.1016/j.ophtha.2017.05.035 10.1016/j.ijsu.2010.02.007 10.1111/j.1600-0420.2006.00696.x 10.1001/archopht.1997.01100150618007 10.1016/j.ophtha.2010.08.044 10.1016/j.ophtha.2005.12.013 10.1007/s00417-014-2591-9 10.1038/s41598-018-26629-5 10.1001/archopht.117.5.664 10.1111/j.1755-3768.2016.0297 10.18637/jss.v036.i03 10.1159/000371584 10.1002/sim.1186 10.1016/S0161-6420(96)30593-9 10.1136/bjo.2010.187773 10.1001/jamaophthalmol.2018.2620 10.1001/archopht.116.8.1031 10.1016/j.puhe.2014.10.012 10.18637/jss.v036.i11 10.1001/jama.283.15.2008 10.1111/j.1755-3768.2015.0398
ContentType	Journal Article
Copyright	Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. 2020 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml	– notice: Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2020 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1136/bjophthalmol-2019-314422
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE ProQuest One Academic Middle East (New) MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1468-2079
EndPage	1084
ExternalDocumentID	31712255 10_1136_bjophthalmol_2019_314422 bjophthalmol
Genre	Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article
GeographicLocations	Europe United Kingdom--UK Germany
GeographicLocations_xml	– name: Europe – name: United Kingdom--UK – name: Germany
GroupedDBID	--- -~X .55 .GJ .VT 0R~ 18M 23N 2WC 354 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN ABAAH ABJNI ABKDF ABMQD ABTFR ABUWG ABVAJ ACCCW ACGFO ACGFS ACGTL ACHTP ACMFJ ACNCT ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FYUFA H13 HAJ HMCUK HYE HZ~ IAO IEA IHR IOF ITC J5H KQ8 L7B M1P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 W8F WH7 WOQ X7M XOL YFH YQY ZGI AAFWJ AAYXX ACQHZ AERUA AFFHD CITATION PHGZM PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8
ID	FETCH-LOGICAL-b387t-b25a9ba2fec3458af79fddc0e9bb4af01cc89ade918defcf6050a9903d0c41693
IEDL.DBID	BENPR
ISICitedReferencesCount	256
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000602289600009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0007-1161 1468-2079
IngestDate	Sun Nov 09 09:49:45 EST 2025 Tue Oct 07 07:36:55 EDT 2025 Thu Apr 03 07:08:17 EDT 2025 Sat Nov 29 03:06:05 EST 2025 Tue Nov 18 22:18:27 EST 2025 Thu Apr 24 22:51:15 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	8
Keywords	epidemiology retina macula
Language	English
License	Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b387t-b25a9ba2fec3458af79fddc0e9bb4af01cc89ade918defcf6050a9903d0c41693
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ORCID	0000-0002-9771-3431
PMID	31712255
PQID	2433227666
PQPubID	2041039
PageCount	8
ParticipantIDs	proquest_miscellaneous_2314022475 proquest_journals_2433227666 pubmed_primary_31712255 crossref_citationtrail_10_1136_bjophthalmol_2019_314422 crossref_primary_10_1136_bjophthalmol_2019_314422 bmj_primary_10_1136_bjophthalmol_2019_314422
PublicationCentury	2000
PublicationDate	20200800 2020-08-00 20200801
PublicationDateYYYYMMDD	2020-08-01
PublicationDate_xml	– month: 08 year: 2020 text: 20200800
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	British journal of ophthalmology
PublicationTitleAlternate	Br J Ophthalmol
PublicationYear	2020
Publisher	BMJ Publishing Group LTD
Publisher_xml	– name: BMJ Publishing Group LTD
References	Cachulo, Lobo, Figueira 2015; 233 Klein, Klein, Knudtson 2006; 113 Cochran 1950; 37 Akuffo, Nolan, Stack 2015; 99 Downie, Makrai, Bonggotgetsakul 2018; 136 Stroup, Berlin, Morton 2000; 283 Erke, Bertelsen, Peto 2012; 119 de, Dossarps, Gabrielle 2015; 93 JLY, Khawaja, Chan 2015; 129 Björnsson, Syrdalen, Bird 2006; 84 Vingerling, Dielemans, Hofman 1995; 102 Topouzis, Coleman, Harris 2006; 142 Jonasson, Arnarsson, Peto 2005; 112 Rudnicka, Jarrar, Wormald 2012; 119 Klaver, Assink, van Leeuwen 2001; 42 Jonasson, Arnarsson, Eiríksdottir 2011; 118 Creuzot-Garcher, Binquet, Daniel 2016; 94 Hirvelä, Luukinen, Läärä 1996; 103 Viechtbauer 2010; 36 Lewis, Ellis 1982 Peters 2006; 295 Higgins, Thompson 2002; 21 Buch, Nielsen, Vinding 2005; 112 Rudnicka, Kapetanakis, Jarrar 2015; 160 Delcourt, Lacroux, Carrière 2005; 140 JQ, Terheyden, Welchowski 2018 Delcourt, Korobelnik, Barberger-Gateau 2010; 14 Krasnik, Stefanickova, Popov 2018; 33 Wong, Su, Li 2014; 2 Korb, Kottler, Wolfram 2014; 252 Brandl, Breinlich, Stark 2016; 11 Pagliarini 1997; 115 Piermarocchi, Segato, Scopa 2011; 18 Saunier, Merle, Delyfer 2018; 136 Brandl, Zimmermann, Günther 2018; 8 Klein, Meuer, Myers 2014; 21 Colijn, Buitendijk, Prokofyeva 2017; 124 Schwarzer 2007; 7 Klein, Myers, Buitendijk 2014; 158 Brandll, Stark, Olden 2016; 94 2011; 95 Augood, Vingerling, de Jong 2006; 124 Bird, Bressler, Bressler 1995; 39 Kozobolis 1999; 117 Moher, Liberati, Tetzlaff 2010; 8 Ferris, Wilkinson, Bird 2013; 120 Wilde, Poostchi, Mehta 2017; 31 Delcourt, Diaz, Ponton-Sanchez 1998; 116 2020080315452601000_104.8.1077.17 2020080315452601000_104.8.1077.18 2020080315452601000_104.8.1077.15 2020080315452601000_104.8.1077.16 2020080315452601000_104.8.1077.13 2020080315452601000_104.8.1077.14 2020080315452601000_104.8.1077.11 2020080315452601000_104.8.1077.19 2020080315452601000_104.8.1077.8 2020080315452601000_104.8.1077.20 2020080315452601000_104.8.1077.3 2020080315452601000_104.8.1077.21 2020080315452601000_104.8.1077.1 2020080315452601000_104.8.1077.6 2020080315452601000_104.8.1077.7 2020080315452601000_104.8.1077.4 2020080315452601000_104.8.1077.5 JLY (2020080315452601000_104.8.1077.36) 2015; 129 2020080315452601000_104.8.1077.48 2020080315452601000_104.8.1077.49 2020080315452601000_104.8.1077.46 Saunier (2020080315452601000_104.8.1077.23) 2018; 136 2020080315452601000_104.8.1077.45 Wong (2020080315452601000_104.8.1077.2) 2014; 2 Hirvelä (2020080315452601000_104.8.1077.43) 1996; 103 2020080315452601000_104.8.1077.10 2020080315452601000_104.8.1077.51 2020080315452601000_104.8.1077.52 2020080315452601000_104.8.1077.50 2020080315452601000_104.8.1077.39 2020080315452601000_104.8.1077.37 2020080315452601000_104.8.1077.38 Schwarzer (2020080315452601000_104.8.1077.12) 2007; 7 2020080315452601000_104.8.1077.34 Delcourt (2020080315452601000_104.8.1077.31) 1998; 116 Klaver (2020080315452601000_104.8.1077.25) 2001; 42 Creuzot-Garcher (2020080315452601000_104.8.1077.33) 2016; 94 Klein (2020080315452601000_104.8.1077.44) 2014; 21 2020080315452601000_104.8.1077.42 Krasnik (2020080315452601000_104.8.1077.47) 2018; 33 2020080315452601000_104.8.1077.40 2020080315452601000_104.8.1077.29 2020080315452601000_104.8.1077.26 Downie (2020080315452601000_104.8.1077.28) 2018; 136 Cachulo (2020080315452601000_104.8.1077.41) 2015; 233 2020080315452601000_104.8.1077.24 2020080315452601000_104.8.1077.22 Rudnicka (2020080315452601000_104.8.1077.27) 2015; 160 Wilde (2020080315452601000_104.8.1077.35) 2017; 31 2020080315452601000_104.8.1077.32 2020080315452601000_104.8.1077.30 Korb (2020080315452601000_104.8.1077.9) 2014; 252 32060040 - Br J Ophthalmol. 2020 Apr;104(4):449-450
References_xml	– volume: 112 start-page: 132 year: 2005 article-title: 5-Year incidence of age-related maculopathy in the Reykjavik eye study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2004.07.020 – volume: 31 start-page: 1042 year: 2017 article-title: Prevalence of age-related macular degeneration in an elderly UK Caucasian population—The Bridlington eye assessment project: a cross-sectional study publication-title: Eye doi: 10.1038/eye.2017.30 – volume: 295 start-page: 676 year: 2006 article-title: Comparison of two methods to detect publication bias in meta-analysis publication-title: JAMA doi: 10.1001/jama.295.6.676 – volume: 140 start-page: 924 year: 2005 article-title: The Three-Year Incidence of Age-Related Macular Degeneration: The “Pathologies Oculaires Liées à l’Age” (POLA) Prospective Study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2005.05.002 – start-page: 1 year: 2018 article-title: Prevalence of retinal vein occlusion in Europe: a systematic review and meta-analysis publication-title: Ophthalmologica – volume: 14 start-page: 854 year: 2010 article-title: Nutrition and age-related eye diseases: the Alienor (Antioxydants, lipides essentiels, nutrition et maladies oculaires) study publication-title: J Nutr Health Aging doi: 10.1007/s12603-010-0131-9 – volume: 160 start-page: 85 year: 2015 article-title: Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2015.04.003 – volume: 94 start-page: e90 year: 2016 article-title: The Montrachet study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population publication-title: Acta Ophthalmol doi: 10.1111/aos.12842 – volume: 33 start-page: 506 year: 2018 article-title: Prevalence of age-related macular degeneration in Slovakia and associated risk factors: a mobile clinic-based cross-sectional epidemiological survey publication-title: Semin Ophthalmol doi: 10.1080/08820538.2017.1316861 – volume: 119 start-page: 571 year: 2012 article-title: Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.09.027 – volume: 99 start-page: 1037 year: 2015 article-title: Prevalence of age-related macular degeneration in the Republic of Ireland publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2014-305768 – volume: 37 start-page: 256 year: 1950 article-title: The comparison of percentages in matched samples publication-title: Biometrika doi: 10.1093/biomet/37.3-4.256 – volume: 112 start-page: 787 year: 2005 article-title: 14-Year incidence, progression, and visual morbidity of age-related MaculopathyThe Copenhagen City eye study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2004.11.040 – volume: 158 start-page: 513 year: 2014 article-title: Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration Consortium publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.05.027 – volume: 142 start-page: 1076 year: 2006 article-title: Prevalence of age-related macular degeneration in Greece: the Thessaloniki eye study publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2006.07.042 – volume: 124 start-page: 529 year: 2006 article-title: Prevalence of age-related maculopathy in older Europeans: the European eye study (EUREYE) publication-title: Arch Ophthalmol doi: 10.1001/archopht.124.4.529 – volume: 119 start-page: 1737 year: 2012 article-title: Prevalence of age-related macular degeneration in elderly Caucasians: the Tromsø eye study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.03.016 – volume: 120 start-page: 844 year: 2013 article-title: Clinical classification of age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2012.10.036 – volume: 116 start-page: 1031 year: 1998 article-title: Smoking and age-related macular degeneration. The polA study. pathologies Oculaires Liees a l'Age publication-title: Arch Ophthalmol – volume: 39 start-page: 367 year: 1995 article-title: An international classification and grading system for age-related maculopathy and age-related macular degeneration publication-title: Surv Ophthalmol doi: 10.1016/S0039-6257(05)80092-X – volume: 7 start-page: 40 year: 2007 article-title: Meta: an R package for meta-analysis publication-title: R news – volume: 21 start-page: 14 year: 2014 article-title: Harmonizing the classification of age-related macular degeneration in the three-continent AMD Consortium publication-title: Ophthalmic Epidemiol doi: 10.3109/09286586.2013.867512 – start-page: 31 year: 1982 article-title: A statistical appraisal of post-infarction beta-blocker trials publication-title: Prim Cardiol – volume: 136 start-page: 473 year: 2018 article-title: Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR study publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.0504 – volume: 2 start-page: e106 year: 2014 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 42 start-page: 2237 year: 2001 article-title: Incidence and progression rates of age-related maculopathy: the Rotterdam study publication-title: Invest Ophthalmol Vis Sci – volume: 11 year: 2016 article-title: Features of age-related macular degeneration in the general adults and their dependency on age, sex, and smoking: results from the German KorA study publication-title: PLoS One doi: 10.1371/journal.pone.0167181 – volume: 93 year: 2015 article-title: Prevalence of age-related macular diseases in an old French population (the MONTRACHET Study) [abstract] publication-title: Acta Ophthalmol – volume: 102 start-page: 205 year: 1995 article-title: The prevalence of age-related maculopathy in the Rotterdam study publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)31034-2 – volume: 18 start-page: 129 year: 2011 article-title: The prevalence of age-related macular degeneration in Italy (PAMDI) study: report 1 publication-title: Ophthalmic Epidemiol doi: 10.3109/09286586.2011.574334 – volume: 124 start-page: 1753 year: 2017 article-title: Prevalence of age-related macular degeneration in Europe: the past and the future publication-title: Ophthalmology doi: 10.1016/j.ophtha.2017.05.035 – volume: 8 start-page: 336 year: 2010 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: Int J Surg doi: 10.1016/j.ijsu.2010.02.007 – volume: 84 start-page: 636 year: 2006 article-title: The prevalence of age-related maculopathy (arm) in an urban Norwegian population: the Oslo macular study publication-title: Acta Ophthalmol Scand doi: 10.1111/j.1600-0420.2006.00696.x – volume: 115 start-page: 616 year: 1997 article-title: Age-Related macular disease in rural southern Italy publication-title: Arch Ophthal doi: 10.1001/archopht.1997.01100150618007 – volume: 118 start-page: 825 year: 2011 article-title: Prevalence of age-related macular degeneration in old persons: age, Gene/environment susceptibility Reykjavik study publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.08.044 – volume: 113 start-page: 373 year: 2006 article-title: Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2005.12.013 – volume: 252 start-page: 1403 year: 2014 article-title: Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg health study publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2591-9 – volume: 8 year: 2018 article-title: On the impact of different approaches to classify age-related macular degeneration: results from the German augur study publication-title: Sci Rep doi: 10.1038/s41598-018-26629-5 – volume: 117 start-page: 664 year: 1999 article-title: Correlation between age-related macular degeneration and pseudoexfoliation syndrome in the population of Crete (Greece) publication-title: Arch Ophthal doi: 10.1001/archopht.117.5.664 – volume: 94 year: 2016 article-title: The German augur study: a population-based prospective study to investigate chronic diseases in the elderly with focus on age-related macular degeneration (AMD) publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2016.0297 – volume: 36 start-page: 1 year: 2010 article-title: Conducting Meta-Analyses in R with the metafor Package publication-title: J Stat Softw doi: 10.18637/jss.v036.i03 – volume: 233 start-page: 119 year: 2015 article-title: Prevalence of Age-Related Macular Degeneration in Portugal: The Coimbra Eye Study - Report 1 publication-title: Ophthalmologica doi: 10.1159/000371584 – volume: 283 start-page: 2008 year: 2000 article-title: Meta-Analysis of observational studies in epidemiology: a proposal for reporting publication-title: Jama – volume: 21 start-page: 1539 year: 2002 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 103 start-page: 871 year: 1996 article-title: Risk factors of age-related maculopathy in a population 70 years of age or older publication-title: Ophthalmology doi: 10.1016/S0161-6420(96)30593-9 – volume: 95 start-page: 931 year: 2011 article-title: Prevalence of age-related macular degeneration in Spain publication-title: Br J Ophthalmol doi: 10.1136/bjo.2010.187773 – volume: 136 start-page: 1051 year: 2018 article-title: Appraising the quality of systematic reviews for age-related macular degeneration interventions publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.2620 – volume: 129 start-page: 103 year: 2015 article-title: Area deprivation and age related macular degeneration in the EPIC-Norfolk eye study publication-title: Public Health – volume: 252 start-page: 1403 year: 2014 ident: 2020080315452601000_104.8.1077.9 article-title: Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg health study publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2591-9 – ident: 2020080315452601000_104.8.1077.20 – ident: 2020080315452601000_104.8.1077.46 doi: 10.1016/j.ajo.2014.05.027 – ident: 2020080315452601000_104.8.1077.42 doi: 10.1111/j.1600-0420.2006.00696.x – ident: 2020080315452601000_104.8.1077.40 doi: 10.1016/j.ophtha.2010.08.044 – ident: 2020080315452601000_104.8.1077.19 doi: 10.1016/j.ophtha.2011.09.027 – ident: 2020080315452601000_104.8.1077.18 doi: 10.1001/jama.295.6.676 – volume: 7 start-page: 40 year: 2007 ident: 2020080315452601000_104.8.1077.12 article-title: Meta: an R package for meta-analysis publication-title: R news – ident: 2020080315452601000_104.8.1077.15 doi: 10.1002/sim.1186 – ident: 2020080315452601000_104.8.1077.38 doi: 10.3109/09286586.2011.574334 – ident: 2020080315452601000_104.8.1077.50 doi: 10.1016/j.ophtha.2012.03.016 – ident: 2020080315452601000_104.8.1077.26 doi: 10.1038/s41598-018-26629-5 – ident: 2020080315452601000_104.8.1077.6 – ident: 2020080315452601000_104.8.1077.10 doi: 10.1371/journal.pone.0167181 – ident: 2020080315452601000_104.8.1077.5 doi: 10.1016/j.ijsu.2010.02.007 – volume: 233 start-page: 119 year: 2015 ident: 2020080315452601000_104.8.1077.41 article-title: Prevalence of Age-Related Macular Degeneration in Portugal: The Coimbra Eye Study - Report 1 publication-title: Ophthalmologica doi: 10.1159/000371584 – ident: 2020080315452601000_104.8.1077.49 doi: 10.1136/bjophthalmol-2014-305768 – volume: 103 start-page: 871 year: 1996 ident: 2020080315452601000_104.8.1077.43 article-title: Risk factors of age-related maculopathy in a population 70 years of age or older publication-title: Ophthalmology doi: 10.1016/S0161-6420(96)30593-9 – ident: 2020080315452601000_104.8.1077.48 doi: 10.1016/j.ajo.2006.07.042 – ident: 2020080315452601000_104.8.1077.7 doi: 10.1016/j.ophtha.2012.10.036 – volume: 116 start-page: 1031 year: 1998 ident: 2020080315452601000_104.8.1077.31 article-title: Smoking and age-related macular degeneration. The polA study. pathologies Oculaires Liees a l'Age publication-title: Arch Ophthalmol doi: 10.1001/archopht.116.8.1031 – ident: 2020080315452601000_104.8.1077.51 doi: 10.1016/S0039-6257(05)80092-X – volume: 21 start-page: 14 year: 2014 ident: 2020080315452601000_104.8.1077.44 article-title: Harmonizing the classification of age-related macular degeneration in the three-continent AMD Consortium publication-title: Ophthalmic Epidemiol doi: 10.3109/09286586.2013.867512 – ident: 2020080315452601000_104.8.1077.37 doi: 10.1001/archopht.1997.01100150618007 – ident: 2020080315452601000_104.8.1077.22 doi: 10.1016/j.ajo.2005.05.002 – volume: 42 start-page: 2237 year: 2001 ident: 2020080315452601000_104.8.1077.25 article-title: Incidence and progression rates of age-related maculopathy: the Rotterdam study publication-title: Invest Ophthalmol Vis Sci – ident: 2020080315452601000_104.8.1077.1 – volume: 129 start-page: 103 year: 2015 ident: 2020080315452601000_104.8.1077.36 article-title: Area deprivation and age related macular degeneration in the EPIC-Norfolk eye study publication-title: Public Health doi: 10.1016/j.puhe.2014.10.012 – ident: 2020080315452601000_104.8.1077.29 doi: 10.1001/archopht.124.4.529 – volume: 160 start-page: 85 year: 2015 ident: 2020080315452601000_104.8.1077.27 article-title: Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2015.04.003 – ident: 2020080315452601000_104.8.1077.45 doi: 10.1016/S0161-6420(95)31034-2 – ident: 2020080315452601000_104.8.1077.30 doi: 10.1111/j.1755-3768.2016.0297 – ident: 2020080315452601000_104.8.1077.32 doi: 10.1007/s12603-010-0131-9 – ident: 2020080315452601000_104.8.1077.39 doi: 10.1136/bjo.2010.187773 – volume: 94 start-page: e90 year: 2016 ident: 2020080315452601000_104.8.1077.33 article-title: The Montrachet study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population publication-title: Acta Ophthalmol doi: 10.1111/aos.12842 – volume: 136 start-page: 473 year: 2018 ident: 2020080315452601000_104.8.1077.23 article-title: Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR study publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.0504 – ident: 2020080315452601000_104.8.1077.14 doi: 10.18637/jss.v036.i11 – ident: 2020080315452601000_104.8.1077.24 doi: 10.1016/j.ophtha.2004.07.020 – ident: 2020080315452601000_104.8.1077.3 doi: 10.1016/j.ophtha.2017.05.035 – ident: 2020080315452601000_104.8.1077.11 doi: 10.1001/archopht.117.5.664 – ident: 2020080315452601000_104.8.1077.17 – volume: 31 start-page: 1042 year: 2017 ident: 2020080315452601000_104.8.1077.35 article-title: Prevalence of age-related macular degeneration in an elderly UK Caucasian population—The Bridlington eye assessment project: a cross-sectional study publication-title: Eye doi: 10.1038/eye.2017.30 – ident: 2020080315452601000_104.8.1077.52 doi: 10.1016/j.ophtha.2005.12.013 – ident: 2020080315452601000_104.8.1077.4 doi: 10.1001/jama.283.15.2008 – ident: 2020080315452601000_104.8.1077.8 – volume: 2 start-page: e106 year: 2014 ident: 2020080315452601000_104.8.1077.2 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 136 start-page: 1051 year: 2018 ident: 2020080315452601000_104.8.1077.28 article-title: Appraising the quality of systematic reviews for age-related macular degeneration interventions publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.2620 – ident: 2020080315452601000_104.8.1077.21 doi: 10.1016/j.ophtha.2004.11.040 – ident: 2020080315452601000_104.8.1077.13 – ident: 2020080315452601000_104.8.1077.16 doi: 10.1093/biomet/37.3-4.256 – volume: 33 start-page: 506 year: 2018 ident: 2020080315452601000_104.8.1077.47 article-title: Prevalence of age-related macular degeneration in Slovakia and associated risk factors: a mobile clinic-based cross-sectional epidemiological survey publication-title: Semin Ophthalmol doi: 10.1080/08820538.2017.1316861 – ident: 2020080315452601000_104.8.1077.34 doi: 10.1111/j.1755-3768.2015.0398 – reference: 32060040 - Br J Ophthalmol. 2020 Apr;104(4):449-450
SSID	ssj0002617
Score	2.6730676
SecondaryResourceType	review_article
Snippet	Background/AimsAge-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of... Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is...
SourceID	proquest pubmed crossref bmj
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1077
SubjectTerms	Age Age Distribution Aged Aged, 80 and over Bias Blindness - epidemiology Classification Epidemiology Estimates Europe - epidemiology European Union - statistics & numerical data Female Humans Incidence Macular degeneration Macular Degeneration - epidemiology Male Meta-analysis Middle Aged Observational Studies as Topic Population Prevalence Sex Distribution Systematic review Trends Vision, Low - epidemiology Visual Acuity
Title	Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis
URI	https://bjo.bmj.com/content/104/8/1077.full https://www.ncbi.nlm.nih.gov/pubmed/31712255 https://www.proquest.com/docview/2433227666 https://www.proquest.com/docview/2314022475
Volume	104
WOSCitedRecordID	wos000602289600009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2079 dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: 7X7 dateStart: 19220101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1468-2079 dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0002617 issn: 0007-1161 databaseCode: BENPR dateStart: 19220101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6RFKFeeNOmlMpIHLG6fiRec6kAteJCVCGQcluNH0upsrtps-X3Y3udFA6gSlz24tdKnz3-PB5_A_AGtSxNzQWVDD2VM84oamWoKhSXzjFujEvJJtR8Xi4W-jw73NY5rHJjE5Ohdp2NPvJjHoW2uAps-2R1RWPWqHi7mlNojGAnKpXJMex8OJ2ff9na4qg3PhBgRVkgN5tYHjE7Npfd6qK_wGXTLcNcYTqYIyljEt2RaS7_3Kb-wj3THnT26H___jE8zOyTvB-myxO459un8OBzvl9_Bk1UdML0Dolg60h0xKeko6SrSbA8ND198Y40mOJXifPfk251hDfUJoNz_x1BcisRTYbnManDxvdIMQuhPIdvZ6dfP36iOSEDNaJUPTV8itogr70VclpirXTtnC28NkZiXTBrS43Oa1Y6X9s6HJUKDNudcIWVUfXlBYzbrvX7QLxWDJWLcn5GzgLJcaZ2nKMVRlghxATeBhSq1SC5UaWjiphVv4NWRdCqAbQJqA1clc3i5jHHxvIOLdm25d1HO9ygXOUlv65uIZ7A621xWKzxBgZb392EOqF9JE1qOoG9YSZtBw1EjgXjOj34d-cvYZfHI3-KQTyEcX9941_Bffuz_7G-PoKRWqj0LY_yWvgFg9oRZQ
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQEXnqUsFDAS3LAaP3YdIyGEgKpV2xWHIu0tjB-hVLvJtpuC-FP8Rmwn2cIB1EsPnOOHEn8ef87MfAPwHLXMTckFlQw9lSPOKGplqMoUl84xboxLxSbUeJxPJvrjCvzsc2FiWGVvE5OhdrWN_8i3eBTa4iqw7TfzExqrRkXval9Co4XFnv_xPVzZFq9334f1fcH59ofDdzu0qypAjchVQw0fojbIS2-FHOZYKl06ZzOvjZFYZszaXKPzmuXOl7YMfD_DYLOFy6yM0iVh3FW4Euy4iiFkarK84CV185ZuK8oCleojh8RoyxzX86PmCKezehqQyXQwflLGkr2rZnb856H4F6abTrztW__bt7oNNztuTd62m-EOrPjqLlw76KIH7sEs6lVhyrIiWDkS3QyppCqpSxLsKk2JPd6RGaboXOL8l6TKHcEbWpPWdfGKIDkXwCZt8k8acOYbpNjJvKzDp0t52fuwVtWVfwDEa8VQuShWaOQoUDhnSsc5WmGEFUIM4GVY9WLeCooU6SImRsXvICkiSIoWJANQPTwK20m3xwoi0wv0ZMueF59ts0dV0Rm0RXEOqQE8Wz4Opij6l7Dy9VloE_pHSqiGA9hokbucNNBUFo6O4cN_D_4Uru8cHuwX-7vjvUdwg8efGynachPWmtMz_xiu2m_N18Xpk7TzCHy-bPj-Au3qbts
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61W1Rx4Q1dKGAkuGFt_Mg6QUIIaFdUhdUKgdRb6idttUmWbgrir_HrsJ1kCwdQLz1wjh9K8nn82TPzDcBTmfNMOcowJ9JiPqYEy1woLBJBuTGEKmVisQkxnWYHB_lsDX72uTAhrLK3idFQm1qHO_IRDUJbVHi2PXJdWMRsZ_Jq8RWHClLB09qX02ghsm9_fPfHt-XLvR3_r59ROtn99PYd7ioMYMUy0WBFU5krSZ3VjKeZdCJ3xujE5kpx6RKidZZLY3OSGeu089w_kd5-M5NoHmRM_LjrsCE8yUgHsPFmdzr7uNoHgtZ5S74FJp5Y9XFEbDxSJ_XiqDmS87Kee5yS3JtCzkMB33VVnvy5Rf6F98b9b3L9f_5yN-Bax7rR63aZ3IQ1W92CzQ9dXMFtKIOSlYz5V0hWBgUHRCy2imqHvMXFMeXHGlTKGLeLjP0S9boDrH1r1Do1XiCJzqWxUZsWFAcsbSOx7ARg7sDnS3nZuzCo6spuAbK5IFKYIGOo-NiTO6OcoVRqpphmjA3huUdAsWilRop4RGPj4nfAFAEwRQuYIYgeKoXuRN1DbZH5BXqSVc-Lz7bdI6zoTN2yOIfXEJ6sHnsjFTxPsrL1mW_j-weyKNIh3GtRvJrUE1jiN5X0_r8HfwybHrXF-73p_gO4SsOtRwzD3IZBc3pmH8IV_a05Xp4-6pYhgsPLxu8voKF4-w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+and+incidence+of+age-related+macular+degeneration+in+Europe%3A+a+systematic+review+and+meta-analysis&rft.jtitle=British+journal+of+ophthalmology&rft.au=Li%2C+Jeany+Q&rft.au=Welchowski%2C+Thomas&rft.au=Schmid%2C+Matthias&rft.au=Mauschitz%2C+Matthias+Marten&rft.date=2020-08-01&rft.eissn=1468-2079&rft.volume=104&rft.issue=8&rft.spage=1077&rft_id=info:doi/10.1136%2Fbjophthalmol-2019-314422&rft_id=info%3Apmid%2F31712255&rft.externalDocID=31712255
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon